Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

612.O1.6 Acute Lymphocytic Leukemia - Biology and Pathophysiology

Sunday, December 7, 2008: 4:30 PM-6:00 PM
Golden Gate Hall (San Francisco Marriott)
Moderators:
Robert Foa and Adolfo A. Ferrando, MD, PhD
4:30 PM
Influence of Race and Nutritional Status on the Long Term Event Free Survival in Childhood Acute Lymphoblastic Leukemia (ALL) : A 14-year Follow-up with a Reduced BFM-Based Treatment Protocol  (GBTLI ALL-93)Clinically Relevant Abstract

Silvia Regina Brandalise1*, Maria Pombo-de-Oliveira2, Vitoria Régia Pereira Pinheiro1*, Maria Jose Mastellaro3*, Waldir Veiga Pereira4*, Marcos Borato Viana5*, Luiz Fernando Lopes6*, Luiz Gonzaga Tone7*, Maria Lucia Lee8*, Paula Bruniera9*, Fernando Almeida Werneck10*, Sonia Rossi Vianna11*, Nubia Mendonça12* and Sandra Regina Loggetto13*

1Pediatric Hematology Oncology, Centro Infantil Boldrini, Campinas, Brazil
2Molecular biology, Instituto Nacional do Cancer, Rio de Janeiro
3Pediatric hematology Oncology, Clemed, Jundiai, Brazil
4Pediatric Hematology Oncology, Universidade Federal de Santa Maria, Snata Maria, Brazil
5Faculdade de Medicina - Depto. Pediatria, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
6Pediatric Hematology Oncology, Hospital A C Camargo, São Paulo, Brazil
7Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, Brazil
8GRAACC - Grupo de Apoio ao Adolescente e à Criança com Câncer, São Paulo, Brazil
9Pediatric Hematology Oncology, Santa Casa de Misericordia de São Paulo, SAO Paulo, Brazil
10Hospital Servidores Públicos do Estado, Rio de Janeiro
11Hospital do Servidor Público Estadual / SP, São Paulo
12Onco Bahia, Salvador, Brazil
13Centro de Hematologia de São Paulo, São Paulo, Brazil

4:45 PM
Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia

Jun J. Yang, PhD1, Wenjian Yang, PhD1*, Cheng Cheng, Ph.D.1*, Meenakshi Devidas, PhD2*, Xueyuan Cao1*, Dario Campana, MD, PhD1, Michael J. Borowitz, MD, PhD3, Cheryl L. Willman, MD4, William Paul Bowman5*, Gregory Reaman, MD6, William L. Carroll, MD7, Stephen P. Hunger, MD8, William E. Evans, Pharm.D.1*, Ching-Hon Pui, M.D.1* and Mary V. Relling, Pharm.D.1*

1St. Jude Children's Research Hospital, Memphis, TN
2Department of Epidemiology & Health Policy Research, University of Florida College of Medicine, Gainesville, FL
3Johns Hopkins University, Baltimore, MD
4University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM
5Cook Childrens Medical Center, Fort Worth, TX
6Children's National Med. Ctr., Washington, DC
7New York University Cancer Institute, New York, NY
8The Children's Hospital and the University of Colorado Denver School of Medicine, Aurora, CO

5:00 PM
Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1

Daniel Trageser1*, Cihangir Duy1*, Lars Klemm1*, Tanja Gruber1*, Rahul Nahar1*, Eugene Park1*, Yong-mi Kim1*, John Groffen1*, Nora Heisterkamp1*, Wolf-Karsten Hofmann, MD2*, Giovanni Martinelli3*, Richard T Williams, MD, PhD4, Hassan Jumaa5* and Markus Muschen1

1Leukemia Research Program, Childrens Hospital Los Angeles, Los Angeles, CA
2MILE Study Group, on Behalf of European LeukemiaNet (ELN, WP13), Munich, Germany
3Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Italy
4Oncology, St. Jude Children's Research Hospital, Memphis, TN
5Molecular Immunology, Max-Planck-Institute for Immunology, Freiburg, Germany

5:15 PM
CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti1, Sarah A. Meadows1*, Adam Kashishian1*, Bart Steiner1*, Sarah May2*, Amy J. Johnson2*, Roger G. Ulrich1*, Albert Yu1*, Michael W. Gallatin1*, John C. Byrd, MD2, Kamal D. Puri1* and Neill A. Giese1*

1Calistoga Pharmaceuticals, Inc, Seatle, WA
2The Ohio State University, Columbus, OH

5:30 PM
Modulation of the Glycolysis Pathway Reverses Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Cells

Esther Hulleman, PhD1*, Mathilde J.C. Broekhuis1*, Karin M Kazemier1*, William E. Evans, PharmD2, Rob Pieters, MD, PhD3 and M. L Den Boer, MSc, PhD4

1Dept. of Pediatrics, Facultybuilding Ee 15-14, Rotterdam, Netherlands
2St. Jude Children's Rsch. Hosp., Memphis, TN
3Dept. of Pediatric Hem./Onc., Erasmus MC, Rotterdam, Netherlands
4Dept. of Pediatric Onc./Hem., Erasmus Medical Center, Rotterdam, Netherlands

5:45 PM
Targeting the Hypoxic Microenvironment by mTOR Inhibitors Sensitizes ALL Cells to Chemotherapy

Olga Frolova, MD, PhD1*, Ismael J. Samudio, PhD1*, Zakar H. Mnjoyan, PhD1*, Hongbo Lu2*, Sergej Konoplev, MD, PhD2, Deborah A. Thomas, MD3, Hagop M. Kantarjian, MD3*, Elizabeth J. Shpall, MD1*, Michael Andreeff, MD, PhD1 and Marina Konopleva, MD, PhD3

1Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

*signifies non-member of ASH